The Myelin Repair Foundation Launches Its Internship Program Examining the Clinical Drug Development Process in Phase 2 and 3 Clinical Trial Failures  
8/30/2012 10:15:09 AM

SARATOGA, Calif.--(BUSINESS WIRE)--The Myelin Repair Foundation (MRF) today announced the launch of its internship program assessing the drug discovery decision-making process in Phase III clinical trial failures. Twenty-six participating graduate students from University of California, Los Angeles will serve as MRF research consultant interns who will apply the comprehensive drug discovery principles established by the Myelin Repair Foundation’s Translational Medicine Platform to 120 drug candidates that previously failed in Phase 2 and 3 trials due to lack of efficacy. Students will acquire in-depth knowledge regarding the clinical drug development process, interact with pharmaceutical industry experts and gain valuable research consulting experience through the MRF Research Consultant Internship program.